$AXGN
Axogen, Inc. Stock $axgn

$axgn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000080592823000051 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$38.16M	$36.66M
YoY Change	10.74%	18.24%
Cost Of Revenue	$7.228M	$6.709M
YoY Change	15.02%	20.97%
Gross Profit	$30.93M	$29.96M
YoY Change	9.79%	17.65%
Gross Profit Margin	81.06%	81.7%
Selling, General & Admin	$30.47M	$30.62M
YoY Change	4.79%	0.36%
% of Gross Profit	98.51%	102.21%
Research & Development	$7.363M	$6.679M
YoY Change	4.86%	6.44%
% of Gross Profit	23.81%	22.3%
Depreciation & Amortization	$798.0K	$709.0K
YoY Change	11.92%	0.71%
% of Gross Profit	2.58%	2.37%
Operating Expenses	$37.83M	$37.30M
YoY Change	4.81%	1.4%
Operating Profit	-$6.902M	-$7.341M
YoY Change	-12.9%	-35.15%
Interest Expense	$148.0K	$16.00K
YoY Change	-40.56%	-95.48%
% of Operating Profit
Other Income/Expense, Net	$242.0K	$267.0K
YoY Change	31.52%	-272.26%
Pretax Income	-$6.660M	-$7.074M
YoY Change	-13.95%	-38.35%
Income Tax
% Of Pretax Income
Net Earnings	-$6.660M	-$7.074M
YoY Change	-13.95%	-38.35%
Net Earnings / Revenue	-17.46%	-19.29%
Basic Earnings Per Share	-$0.16	-$0.17
Diluted Earnings Per Share	-$0.16	-$0.17
COMMON SHARES
Basic Shares Outstanding	42.83M shares	42.60M shares
Diluted Shares Outstanding	42.86M shares	42.57M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.53M	$37.87M
YoY Change	-40.5%	-43.83%
Cash & Equivalents	$23.22M	$7.707M
Short-Term Investments	$11.31M	$30.16M
Other Short-Term Assets	$8.835M	$8.705M
YoY Change	-3.45%	-3.99%
Inventory	$21.24M	$19.85M
Prepaid Expenses
Receivables	$21.57M	$22.28M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$86.18M	$88.70M
YoY Change	-19.29%	-21.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$101.4M	$96.92M
YoY Change	17.98%	17.67%
Goodwill
YoY Change
Intangibles	$4.048M	$3.858M
YoY Change	20.98%	20.94%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$105.5M	$100.8M
YoY Change	18.09%	17.8%
TOTAL ASSETS
Total Short-Term Assets	$86.18M	$88.70M
Total Long-Term Assets	$105.5M	$100.8M
Total Assets	$191.6M	$189.5M
YoY Change	-2.27%	-4.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.89M	$20.19M
YoY Change	4.83%	-3.28%
Accrued Expenses	$1.034M	$1.043M
YoY Change	-41.12%	-49.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.000K	$7.000K
YoY Change	0.0%	-12.5%
Total Short-Term Liabilities	$23.93M	$21.24M
YoY Change	1.41%	-7.44%
LONG-TERM LIABILITIES
Long-Term Debt	$46.15M	$45.93M
YoY Change	1.97%	1.98%
Other Long-Term Liabilities	$24.39M	$24.78M
YoY Change	-4.47%	-5.38%
Total Long-Term Liabilities	$46.15M	$45.93M
YoY Change	1.97%	1.98%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.93M	$21.24M
Total Long-Term Liabilities	$46.15M	$45.93M
Total Liabilities	$94.49M	$91.96M
YoY Change	0.1%	-2.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$273.3M	-$266.7M
YoY Change	9.39%	10.14%
Common Stock	$370.5M	$364.2M
YoY Change	5.38%	5.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$97.15M	$97.51M
YoY Change
Total Liabilities & Shareholders Equity	$191.6M	$189.5M
YoY Change	-2.27%	-4.32%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$6.660M	-$7.074M
YoY Change	-13.95%	-38.35%
Depreciation, Depletion And Amortization	$798.0K	$709.0K
YoY Change	11.92%	0.71%
Cash From Operating Activities	$292.0K	-$7.423M
YoY Change	-105.13%	-32.83%
INVESTING ACTIVITIES
Capital Expenditures	$4.678M	$4.304M
YoY Change	-208.26%	-14.55%
Acquisitions
YoY Change
Other Investing Activities	$19.00M	$3.771M
YoY Change	187.88%	-332.2%
Cash From Investing Activities	$14.32M	-$786.0K
YoY Change	528.43%	-89.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	898.0K	$633.0K
YoY Change	33.83%	566.32%
NET CHANGE
Cash From Operating Activities	292.0K	-$7.423M
Cash From Investing Activities	14.32M	-$786.0K
Cash From Financing Activities	898.0K	$633.0K
Net Change In Cash	15.51M	-$7.576M
YoY Change	-666.54%	-58.37%
FREE CASH FLOW
Cash From Operating Activities	$292.0K	-$7.423M
Capital Expenditures	$4.678M	$4.304M
Free Cash Flow	-$4.386M	-$11.73M
YoY Change	220.85%	-27.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000805928
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityNoncurrent
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityCurrent
CY2023Q1	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityCurrent
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.axogeninc.com/20230331#LeaseLiabilityNoncurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36046
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Axogen, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MN
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	13631 Progress Blvd., Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Alachua,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1301878
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32615
CY2023Q1	dei	City Area Code CityAreaCode	386
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	462-6800
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	AXGN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42832050	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7707000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15284000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15284000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	6252000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	30160000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	33505000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	383000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	650000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22278000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22186000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	19849000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18905000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2453000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1944000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	88699000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98075000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	83049000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79294000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13868000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14369000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3858000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649000	usd
CY2023Q1	us-gaap	Assets Assets	189474000	usd
CY2022Q4	us-gaap	Assets Assets	195387000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	20188000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22443000	usd
CY2023Q1	axgn	Lease Liability Current LeaseLiabilityCurrent	1050000	usd
CY2022Q4	axgn	Lease Liability Current LeaseLiabilityCurrent	1310000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	21238000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23753000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	45931000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	45712000	usd
CY2023Q1	axgn	Lease Liability Noncurrent LeaseLiabilityNoncurrent	20089000	usd
CY2022Q4	axgn	Lease Liability Noncurrent LeaseLiabilityNoncurrent	20405000	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4703000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4518000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	91961000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	94388000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42809994	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42809994	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42445517	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42445517	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	428000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	424000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	363739000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	360155000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-266654000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-259580000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	97513000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100999000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189474000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195387000	usd
CY2023Q1	us-gaap	Revenues Revenues	36664000	usd
CY2022Q1	us-gaap	Revenues Revenues	31007000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6709000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5546000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	29955000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	25461000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21618000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20888000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6679000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6275000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8999000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9618000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	37296000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	36781000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7341000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11320000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	549000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	-46000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	16000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	354000	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-185000	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	252000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-81000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	267000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-155000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7074000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11475000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42571021	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42571021	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41804330	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41804330	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7074000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11475000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	709000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	704000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	464000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	427000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	71000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	219000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-267000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	267000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	581000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	459000	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-185000	usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	252000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	426000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-96000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2954000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2678000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-175000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	624000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1525000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1166000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	509000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1030000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2442000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1104000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-537000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-320000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	usd
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7423000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11051000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4304000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5037000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10203000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	6024000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	13974000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4400000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	253000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	580000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-786000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7241000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	634000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	97000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	633000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7576000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18197000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21535000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39007000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13959000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20810000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1026000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1119000	usd
CY2023Q1	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	0	usd
CY2022Q1	axgn	Noncash Right Of Use Assets And Operating Lease Liability NoncashRightOfUseAssetsAndOperatingLeaseLiability	641000	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	326000	usd
CY2022Q1	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	239000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100999000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7074000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7074000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2954000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2023Q1	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	634000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	97513000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	112550000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11475000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2678000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022Q1	axgn	Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan	98000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	103851000	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	Nature of Business<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen, Inc. (together with its wholly-owned subsidiaries, the “Company”) was incorporated in Minnesota and is the leader in the science, development and commercialization of the technologies used for peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.</span>The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	6957000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7707000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15284000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15284000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	6252000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13959000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21535000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2147000	usd
CY2022Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1445000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	459000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	709000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12922000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12651000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1070000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1026000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5857000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5228000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	19849000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18905000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	581000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	131000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	131000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	94054000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	89590000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	11005000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	10296000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	83049000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79294000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	704000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5162000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1706000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3456000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4893000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1635000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3258000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5564000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1706000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3858000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5284000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1635000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3649000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	71000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	1298000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	1408000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13868000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14369000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1043000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1303000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20073000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20387000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	35000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	41000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	16000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	18000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1065
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1058
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1207
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.1191
CY2023Q1	axgn	Operating And Financing Lease Liability Noncurrent OperatingAndFinancingLeaseLiabilityNoncurrent	20089000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid Remainder Of Fiscal Year LesseeOperatingAndFinancingLeaseLiabilityToBePaidRemainderOfFiscalYear	2417000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year One LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne	3253000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Two LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo	3336000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Three LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree	3348000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid Year Four LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour	2920000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid After Year Four LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFour	20932000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability To Be Paid LesseeOperatingAndFinancingLeaseLiabilityToBePaid	36206000	usd
CY2023Q1	axgn	Lessee Operating And Financing Lease Liability Undiscounted Excess Amount LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount	15067000	usd
CY2023Q1	axgn	Operating And Financing Lease Liability OperatingAndFinancingLeaseLiability	21139000	usd
CY2023Q1	axgn	Operating And Financing Lease Liability Current OperatingAndFinancingLeaseLiabilityCurrent	1050000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4069000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4288000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	45931000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	45712000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2147000	usd
CY2022Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1445000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	219000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	220000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	6252000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	6251000	usd
CY2023Q1	axgn	Number Of Letters Of Credit NumberOfLettersOfCredit	2	letterofcredit
CY2023Q1	axgn	Number Of Officers NumberOfOfficers	2	officer
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2954000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2678000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7074000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-11475000	usd

Files In Submission

Name	View Source	Status
axgn-20230331_def.xml	Edgar Link	unprocessable
axgn-20230331_cal.xml	Edgar Link	unprocessable
0000805928-23-000051-index-headers.html	Edgar Link	pending
0000805928-23-000051-index.html	Edgar Link	pending
0000805928-23-000051.txt	Edgar Link	pending
0000805928-23-000051-xbrl.zip	Edgar Link	pending
axgn-20230331.htm	Edgar Link	pending
axgn-20230331.xsd	Edgar Link	pending
axgnfy23q1ex311.htm	Edgar Link	pending
axgnfy23q1ex312.htm	Edgar Link	pending
axgnfy23q1ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
axgn-20230331_lab.xml	Edgar Link	unprocessable
axgn-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
axgn-20230331_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXGN
Axogen, Inc. Stock $axgn

2023 Q2 Form 10-Q Financial Statement

#000080592823000051 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN Axogen, Inc. Stock $axgn

2023 Q2 Form 10-Q Financial Statement

#000080592823000051 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXGN
Axogen, Inc. Stock $axgn